Trial Profile
Phase 2 study of oregovomab in combination with a TLR3 agonist, Hiltonol®, in the recurrent ovarian cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2016
Price :
$35
*
At a glance
- Drugs Oregovomab (Primary) ; Poly ICLC
- Indications Ovarian cancer
- Focus Therapeutic Use
- 12 Dec 2016 New trial record